Chronix Biomedical to present trial results of prognostic
test in head/neck cancer at ASCO
Study evaluates Chronix’s CNI-score test for predicting response to therapy and survival outcome compared to currently used approach
San Jose, CA, USA and Göttingen, Germany (24 April 2017) – Chronix Biomedical, Inc., a developer of novel blood-based cancer molecular diagnostics, is pleased to announce that results of a clinical trial of its liquid biopsy test have been accepted for presentation at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting. The abstract will be released on 17 May, ahead of the conference which takes place on 2-6 June, 2017.
The poster presentation1 will cover results of a study evaluating the Copy Number Instability (CNI)-score as a prognostic test in head and neck cancer. The study compares the Chronix CNI-score test’s accuracy as a predictor of time to progression with the current method based on clinical parameters (e.g. staging, invasion of lymph nodes). Predicted time to progression is an important factor that that can aid the therapeutic decision (i.e. adjuvant treatment) in this condition.
Chronix Biomedical’s CEO, Dr Howard B. Urnovitz, commented:
“We are delighted our poster presentation covering this study has been accepted for presentation at ASCO this year. 2017 will now be the third year in succession where we have been able to present clinical data on CNI-score tests for prognostic or therapeutic monitoring applications at this prestigious scientific meeting. We are always pleased to share our results with the oncology community at meetings and through publications in peer reviewed journals.”
Chronix is developing applications for its CNI-score based tests for the prognosis and diagnosis of cancer and, in particular, the real-time therapeutic monitoring of response to cancer therapy. Chronix and its collaborators have shown that its CNI-score based tests can accurately predict whether a patient will respond to treatment after one or two cycles of therapy, potentially 6-8 weeks earlier than is possible using imaging based methods. Such a tool would allow treating physicians to identify non-responding patients quickly and switch them to alternative treatments sooner, avoiding unnecessary side-effects and costs and potentially achieving better treatment outcomes.
The company has presented results at major scientific meetings from studies of its CNI-score based test in therapeutic monitoring applications in patients receiving radiotherapy, chemotherapy2 and immunotherapy3. Results of a clinical study using Chronix’s test in patients receiving immunotherapy in eleven different cancer types were recently published in the journal, Clinical Cancer Research4. The paper is believed to be the first peer-reviewed publication of a therapeutic monitoring strategy with immunotherapy5.
Chronix intends to conduct a number of studies in individual cancers to validate CNI-score tests in specific therapeutic monitoring applications and support regulatory submissions. The first such study, in pancreatic cancer, is already underway and Chronix is finalising the design of similar validation studies in non-small cell lung cancer, melanoma and colorectal cancer.
About Chronix Biomedical
Chronix Biomedical, Inc. is a US-based molecular diagnostics company developing blood tests for the screening and monitoring of cancer. Chronix’s tests use proprietary algorithms to derive a copy number instability (CNI) score from sequencing of circulating cell-free DNA (cfDNA), which can be used in the prognosis, diagnosis and monitoring of therapeutic response to cancer. For more information visit www.chronixbiomedical.com.
1 Abstract 6055. Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer. Monday June 5.
2 Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers, Weiss et al, American Association for Cancer Research 2016 Annual Meeting (see link).
3 Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2” http://meetinglibrary.asco.org/content/166601-176 Weiss et al
4 Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy, Weiss at al. Clin Cancer Res. 2017 Mar 20. pii: clincanres.0231.2017. doi: 10.1158/1078-0432.CCR-17-0231.
5 Based on a literature search conducted on behalf of Chronix Biomedical.